Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

investorenquiries@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

Cancer Therapeutics Research

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

MND Trial Completes Enrolment of First Patient Cohort

MND Trial Completes Enrolment of First Patient Cohort (final)

Category: News & Announcements 2022By PharmAust 02/12/2022

Related posts

Fireside chat with Dr Kim
23/12/2022

PharmAust Canine Trial Update
20/12/2022

PharmAust Receives R&D Tax Incentive Refund
12/12/2022

PhamAust Webinar
17/11/2022

PhamAust AGM 2022
11/11/2022

PharmAust doses first patient with MPL in motor neurone disease trial
03/10/2022

Recent Articles

Data from Canine Oncology Study Supports Progression to Registration Studies
19/10/2023
Chief Executive Officer Appointment
28/08/2023
Additional Phase 1 data suggest MPL may inhibit MND
22/08/2023
Cohort 3 Pharmacokinetics in MND Patients Completed
09/08/2023

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @pharmaust ·

10h

PharmAust on global pharma radar post-Phase I MND trial; could divest vet program – CEO | ION Analytics | @Mergermarket https://mergermarket.ionanalytics.com/content/1003685710

Reply on Twitter 1732011434392035701 Retweet on Twitter 1732011434392035701 Like on Twitter 1732011434392035701 2 Twitter 1732011434392035701

PharmAust @pharmaust ·

4 Dec

PharmAust completes Phase 1 MEND study and files for US Orphan Drug Designation
Via - @PharmaDispatch

Reply on Twitter 1731800187344204140 Retweet on Twitter 1731800187344204140 Like on Twitter 1731800187344204140 8 Twitter 1731800187344204140

Retweet on Twitter PharmAust Retweeted

PharmAust @pharmaust ·

1 Dec

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation via @themarketherald

Reply on Twitter 1730432667206946849 Retweet on Twitter 1730432667206946849 3 Like on Twitter 1730432667206946849 8 Twitter 1730432667206946849

Load More

Copyright © 2023 PharmAust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions